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Brief Report
ABSTRACT
Coagulation alterations may be involved in osteonecrosis in childhood acute lymphoblastic leukemia. Retrospectively, we evaluated the
available coagulation parameters at diagnosis and during induction treatment of 161 acute lymphoblastic leukemia patients: 24 with
symptomatic osteonecrosis (median age: 13.8 years, range 4.0–17.2) and 137 without osteonecrosis (median age: 4.9 years, range
1.0-16.7). Coagulation parameters of both groups were similar at diagnosis. After four weeks of treatment including dexamethasone, lev-
els of antithrombin and protein S were significantly less in osteonecrosis-positive than in osteonecrosis-negative patients. Subsequently,
after four doses of asparaginase and tapering dexamethasone, these coagulation parameters equally decreased in both groups.
Consequently, nadirs of antithrombin and protein S were significantly lower in osteonecrosis-positive than in osteonecrosis-negative
patients, even reaching levels below lower normal limits in the osteonecrosis-positive group. A reduced dexamethasone related increase
of antithrombin and protein S, and subsequent decline below normal levels after introduction of asparaginase, may result in a hyperco-
agulable state, contributing to development of symptomatic osteonecrosis.
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Introduction
Because the cure-rate of acute lymphoblastic leukemia
(ALL) is high, attention has shifted to its side-effects during
and after therapy. One of these serious complications is
osteonecrosis (ON), which is caused by impairment of mi-
crocirculation serving a segment of bone that has a poor col-
lateral circulation and insufficient venous drainage.1,2 
Hypercoagulability may play a role in the etiology of ON
in childhood ALL.3-5 Dexamethasone and asparaginase,
important drugs in the induction treatment of childhood
ALL, can influence the coagulation system.6-10 Corticosteroids
increase most coagulation-protein concentrations, whereas
asparaginase can reduce the synthesis of coagulation factors
and inhibitors. Micro-thrombi resulting from an imbalance
between procoagulant and anticoagulant processes in
patients with Legg-Calvé-Perthes disease have been shown
to play an important etiological role in the development of
ON.11-13 Little information is available on the role of coagula-
tion dysregulation in the pathogenesis of ON in childhood
ALL.3,4,14
Therefore, the main objective of this study is to investigate
whether induction-therapy-related alterations in coagulation
are associated with the development of symptomatic ON
during childhood ALL. For this reason procoagulant factors,
anticoagulant factors, parameters of thrombin generation,
and parameters of fibrinolysis were evaluated.
Design and Methods
Patients 
Differences in coagulation parameters between childhood
ALL patients with and without symptomatic ON were stud-
ied in a retrospective analysis. Between 1997 and 2004, 174
patients received induction therapy according to the Dutch
Childhood Oncology Group(DCOG)-ALL9 treatment proto-
col. The purpose of this dexamethasone-based protocol was
to reproduce the results of the DCOG-ALL6 treatment proto-
col in a larger cohort of Dutch ALL patients; it included
induction therapy as shown in Figure 1.15 Since patients
received four weeks of dexamethasone prior to any asparag-
inase exposure, we had a unique opportunity to evaluate the
effect of the separate agents on coagulation parameters.
Patients were treated according to the high-risk proto-
col based on white-cell count ≥50×109, T-cell
immunophenotype, mediastinal mass, involvement of
the central nervous system, infiltration of the testes,
and t(9;22) or 11q23 rearrangements; all other patients
received the non-high-risk protocol. Cumulative doses
of the chemotherapeutic agents used in the DCOG-
ALL9 protocol have been previously reported.16 In this
protocol newly diagnosed ALL patients older than 365
days and younger than 19 years were included, with
exception of mature B-cell ALL patients. Coagulation
parameters, which were routinely measured during
induction therapy to monitor asparaginase toxicity,
were available for 161 patients (24 developed sympto-
matic ON). No patient received plasma or cryoprecipi-
tate during the study period.
Clinical data (age, gender, immunophenotype of
leukemia) and data on thrombotic events during inten-
sification and maintenance phase were collected from
the medical records. The study was approved by the
Medical Ethics Committee of the Erasmus Medical
Center, Rotterdam and written informed consent was
obtained from all participants and/or their parents.
Methods
Patients were considered ON-positive if they had
developed symptomatic ON during treatment or with-
in one year after cessation of treatment. For this study
we aimed to investigate clinical relevant symptomatic
ON.17 Symptomatic ON was defined as persistent pain
in the arms or legs not associated with recent vin-
cristine administration, in combination with typical
findings on magnetic resonance imaging(MRI).18
Peripheral-blood samples were taken at diagnosis
and at five time points (days 29, 33, 36, 40 and 43) dur-
ing induction therapy of ALL (Figure 1). On days 29, 33,
36 and 40, peripheral-blood samples were taken imme-
diately before each asparaginase infusion. Using sam-
ple tubes containing a fixed amount of citrate, we
determined procoagulant factors(fibrinogen and factor
II,V,VII,IX,X), anticoagulant factors(antithrombin, pro-
tein C and protein S), parameters of thrombin genera-
tion (prothrombin fragment 1+2(F1+2) and thrombin-
antithrombin complex(TAT)) and parameters of fibri-
nolysis(a2-antiplasmin (a2AP), plasminogen, plasmin-
a2AP complex(PAP), D-dimers). Samples were chilled
immediately on ice and centrifuged 30 mins. at 20,000
rpm at 4°C. The supernatant was withdrawn and
stored until the time of analysis at -80°C. 
Coagulation assays
Fibrinogen was determined using the Claus method19
(Dade® Thrombin Reagent; Dade Behring GmbH,
Marburg, Germany). Factor II,V,VII,IX and X were
assessed using factor-deficient plasma and standard
one-stage factor assays (Coagulation Factor II,VII and
X, Coagulation Factor V Deficient Plasma and
Coagulation Factor IX; Dade Behring GmbH, Marburg,
Germany). The anticoagulants antithrombin and pro-
tein C activity were measured using Berichrom
Antithrombin III(A) and Berichrom Protein C(Dade
Behring GmbH, Marburg, Germany). Total and free
protein S were determined using enzyme-linked
immunosorbent assays(ELISA)(Asserachrom® Total
Protein S and Asserachrom® Free Protein S; Diagnostica
Stago, Asnieres, France). Plasminogen and α2-AP were
measured using Berichrom A2-Antiplasmin and
Berichrom Plasminogen(Dade Behring GmbH,
Marburg, Germany). PAP was measured using PAP
micro ELISA(Dade Behring GmbH, Marburg,
Germany).20 D-dimer levels were measured with an
immunoturbidimetric assay(Auto Dimer®; Trinity
Biotech plc, Bray, Ireland). The markers of endogenous
thrombin generation F1+2 and TAT were measured
using ELISA(Enzygnost F1+2 and Enzygnost TAT;
Dade Behring GmbH, Marburg, Germany).21
Data analysis
The Mann-Whitney U-test and the χ2-test/Fisher-
exact test were used to compare patients’ characteris-
tics between the ON-positive and ON-negative groups.
Coagulation parameters of the ON-positive and ON-
negative patients were compared with the non-para-
metric Mann-Whitney U-test. These statistical analyses
were carried out with SPSS for Windows version 11.0.1
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Figure 1. Antithrombin (A) and protein S (B) at diagnosis and dur-
ing Dutch Childhood Oncology Group (DCOG)-ALL9 induction treat-
ment in childhood patients who did and did not develop sympto-
matic osteonecrosis. SEM: standard error of the mean; i.v., intra
venous. Normal reference ranges are marked with dotted horizon-
tal lines; antithrombin: 0.8-1.2 IU/mL and protein S: 0.7-1.4
IU/mL. p values indicate differences between patients with and
without symptomatic osteonecrosis at each moment (mixed-
model analysis of repeated measures). 
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(SPSS Inc., Chicago, IL, USA). 
Repeated-measurements analysis (SAS PROC
MIXED; SAS Institute Inc., Cary, North Carolina, USA)
was used to confirm differences in antithrombin, pro-
tein C and protein S between both groups. To analyze
differences between the ON-positive and the ON-neg-
ative groups in trends over time of antithrombin, pro-
tein C and protein S, the model defined by the variables
time, ON-group and the interaction variable time*ON-
group were applied (Figure 1). We used an unstructured
repeated covariance type. Differences between ON-
positive and ON-negative patients at each moment
were estimated using a model without intercept
defined by the interaction variable ON-group*time. The
same model was used for evaluation of the slopes of
the curves of the anticoagulants over time. p values
under 0.05 (two-sided) were considered statistically
significant.
Results and Discussion
Patients’ characteristics
Clinical characteristics of ON-positive and ON-nega-
tive patients are summarized in Table 1. No differences
were found between ON-positive and ON-negative
patients in gender, immunophenotype of leukemia and
risk-group stratification. As expected, the median age
at diagnosis of ALL was significantly higher in ON-pos-
itive than in ON-negative patients. ON was confirmed
by MRI in all cases. All but one of the ON-positive
patients were diagnosed with ON before stop of treat-
ment; the patient diagnosed after stop of treatment
already had symptoms during treatment, which were
thought to be due to vincristine. Only after cessation of
treatment did it become apparent that the patient had
ON and this was confirmed by a delayed MRI.
At a later stage during treatment, i.e. intensification
and maintenance treatment of the DCOG-ALL9 sched-
ule, 3 out of 24 ON-positive patients (12.5%) endured
a thrombotic event, as compared to 2 out of 137 (1.5%)
ON-negative patients (χ2-test, p=0.02). The thrombotic
events included one transverse sinus thrombosis, one
pulmonary embolism and a thrombus of the brachio-
cephalic vein possibly related to the presence of an
implantable venous access port (Port-A-Cath) in the
ON-positive patients. In the group of ON-negative
patients, one transverse sinus thrombosis and one
catheter related thrombosis in the upper venous system
of the arm occurred. 
Coagulation parameters at diagnosis
Values of the coagulation parameters at diagnosis are
summarized in Table 2. At diagnosis no significant dif-
ferences in any of the coagulation parameters between
ON-negative patients and ON-positive patients were
observed. Values of the anticoagulant factors antithrom-
bin, protein C activity and total protein S were all with-
in normal ranges for both groups (Figure 1). 
Coagulation parameters during induction treatment
Results of all coagulation parameters measured dur-
ing DCOG-ALL9 induction therapy after a four-week
treatment with dexamethasone (day 29) are shown in
Table 2. Mean values of the anticoagulants antithrom-
bin and total protein S after four weeks of induction
treatment with dexamethasone at day 29 and during
tapering of dexamethasone and administration of four
doses asparaginase (day 33-43) are shown in Figure 1.
Values of antithrombin and total protein S, but not of
protein C, were significantly lower in ON-positive
patients than in ON-negative patients after four weeks
of dexamethasone administration (p<0.05 and p<0.05).
Mixed-model analysis of repeated measures showed a
significant decrease in ON-positive patients of
antithrombin (p<0.001) and total protein S (p<0.001)
during days 29-43 and also in ON-negative patients
there was a significant decrease of antithrombin
(p<0.001) and protein S (p<0.001) from day 29-43
(Figure 1). This decrease of AT and total protein S dur-
ing tapering of dexamethasone and administration of
four doses of asparaginase was equal in both ON-posi-
tive and ON-negative patients, which resulted in a
decline below lower normal limits of antithrombin and
protein S in ON-positive patients but not in ON-nega-
tive patients. 
Factor X was different between ON-positive and
ON-negative patients at day 29, but absolute levels
stayed within the normal range in both groups at all
time points. Dexamethasone-induced or asparaginase-
induced differences in any of the other coagulation
parameters between ON-negative and ON-positive
patients were not found at any time point during induc-
tion treatment.
Osteonecrosis is a disabling complication which may
occur during ALL treatment. Although several etiologi-
cal factors have been suggested, the pathophysiology
of ON is not entirely understood. It has been suggested
that a deviation of the coagulation system is one of the
predisposing factors, but until now only a few studies
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Table 1. Clinical characteristics of patients with and without symp-
tomatic osteonecrosis. 
Clinical data Patients with Patients p value
osteonecrosis without 
osteonecrosis
Patients at diagnosis (n=) 24 137 -
Gender (male/female) 12 / 12 81 / 56 0.40
Age at ALL diagnosis 13.8 (4.0–17.2) 4.9 (1.0–16.7) <0.01
median (range) in years
Age at diagnosis of 16.1 (6.0–18.7) N.A. -
osteonecrosis 
median (range) in years
Immunophenotype 
precursor-B 20 (83%) 116 (85%) 0.77
T 4 (17%) 21 (15%)
Risk-group stratification
Non-high risk 18 (75%) 93 (68%) 0.63
High risk 6 (25%) 44 (32%)
ALL: acute lymphoblastic leukemia; N.A.: not applicable. 
p value: Mann-Whitney U-test/χ2 test/Fisher exact test. 
have been performed on coagulation dysregulation in
the pathogenesis of ON in childhood.11-13 In 1989,
Hanada et al. suggested that L-asparaginase induced
coagulopathy in a child with ALL related osteonecro-
sis.5 A study investigating the prevalence of hereditary
prothrombotic risk factors such as factor V Leiden, the
prothrombin 20210G>A polymorphism and the meth-
ylene tetrahydrofolate reductase 677C>T variant in a
group of 24 children who developed ON during treat-
ment for various types of cancer, including 16 cases of
ALL, did not identify an increased prevalence of these
hypercoagulable state mutations.3 In a previous study,
we showed that the number of kringle-IV repeats in the
Apo(a) gene and lipoprotein(a) levels did not contribute
to an increased risk of symptomatic ON during child-
hood ALL.4 Recently PAI-1 genetic variation was
described as contributing to the risk of osteonecrosis in
children with ALL.14 The present study is the first to
investigate the influence of coagulation disturbance
during induction treatment, as measured by procoagu-
lant factors, anticoagulant factors, parameters of
thrombin generation and parameters of fibrinolysis, on
the development of symptomatic ON in a single-center
cohort of children with ALL, treated according to one
risk-stratified treatment protocol. 
We found no differences in coagulation parameters at
diagnosis between the ALL patients who developed
ON and patients who did not. This suggests that there
are no important pre-existent patient-specific or
leukemia-related coagulation aberrations that play a
role in the pathogenesis of ON in childhood ALL. 
We suggest that asparaginase plays an important role
in the development of symptomatic ON in ALL
patients, illustrated by the significant decrease of
antithrombin and protein S in all patients after the
introduction of this drug. However, our results show
that the preceding administration of dexamethasone
might play an even more discriminative role for devel-
oping ON. ON-positive ALL patients showed a less
impressive and significantly different increase in
antithrombin and protein S after administration of dex-
amethasone. A subsequent decrease of antithrombin
and protein S levels below the lower limit of normal in
the ON-positive patients did not become manifest until
asparaginase administration. This may indicate a ther-
apy-induced hypercoagulable state in this subgroup of
ALL patients, contributing to the development of ON.
As total protein S levels were determined only in a suf-
ficient number of patients, it remains unknown
whether free protein S levels were also reduced, which
may be more clinically relevant. 
Previous studies showed that ON is a serious compli-
cation of childhood ALL treatment, especially in
teenagers.22,23 The higher incidence of ON in older chil-
dren has not yet been explained. The majority of the
ON-positive patients in our study were above the age of
ten years (79%). Although in the total group of patients
high levels of antithrombin and protein S after four
weeks of dexamethasone treatment were found, sub-
group analyses showed a significantly different increase
in levels of these anticoagulants in children older than
ten years of age as compared to the younger ALL
patients.24 As our group of ON-positive patients was sig-
nificantly older than the group of ON-negative patients,
we suggest that age-related differences in dexametha-
sone-induced changes in the coagulation system may
contribute to this higher incidence of ON at an older
age. Considering the limitations of our retrospective
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Table 2. Coagulation parameters at diagnosis and after four weeks induction therapy with dexamethasone of pediatric patients with
acute lymphoblastic leukemia who did and did not develop osteonecrosis.
Coagulation Normal Diagnosis Diagnosis After 4 weeks After 4 weeks 
variable ranges dexamethasone dexamethasone
ON-pos. ON-pos. ON-neg. ON-neg. p ON-pos. ON-pos. ON-neg. ON-neg. p
(N=) Median (range) (N=) Median (range) (N=) Median (range) (N=) Median (range)
PT (sec) 10.9-13.3 21 14.0 (10.0-21.5) 107 13.1(10.0-29.0) 0.71
APTT (sec) 28-39 23 34 (19-48) 136 34 (20-56) 0.77
Fibrinogen (g/L) 1.5-3.6 24 3.2 (1.7-4.7) 137 3.0 (0.8-7.8) 0.69 9 0.9 (0.1-2.1) 78 1.3 (0.1-3.9) 0.11
Antithrombin (IU/mL) 0.80-1.20 13 0.93 (0.51-1.20) 84 0.94 (0.47-1.44) 0.41 9 1.29 (0.96-1.68) 78 1.47 (1.03-2.02) <0.05
ProtCact (IU/mL) 0.70-1.40 9 0.68 (0.53-1.09) 59 0.72 (0.37-1.29) 0.66 9 1.56 (0.94-2.96) 78 1.84 (0.84-3.29) 0.09
ProtSfree (IU/mL) 0.76-1.28 3 0.51 (0.29-0.64) 26 0.58 (0.21-1.07) 0.45 9 0.89 (0.63-1.50) 78 1.00 (0.11-1.54) 0.17
ProtStotal (IU/mL) 0.70-1.40 7 0.66 (0.56-1.08) 33 0.74 (0.33-1.49) 0.46 9 0.81 (0.64-1.53) 78 1.03 (0.28-1.53) <0.05
Plasminogen (IU/mL) 0.85-1.20 6 0.86 (0.76-1.29) 33 1.03 (0.43-1.49) 0.52 9 1.04 (0.67-1.61) 76 1.21 (0.80-2.34) 0.08
a2AP (IU/mL) 0.80-1.20 6 1.04 (0.92-1.20) 33 1.10 (0.42-1.35) 0.21 9 1.27 (0.97-1.65) 76 1.41 (0.95-2.82) 0.06
D-dimers (mg/L) 0-0.25 13 0.33 (0.10-3.21) 59 0.40 (0.03-4.77) 0.11 7 0.16 (0.07-0.47) 62 0.11 (0.02-0.64) 0.20
Factor II (IU/mL) 0.60-1.40 6 0.52 (0.49-1.33) 33 0.70 (0.24-1.12) 0.53 9 1.21 (0.47-1.39) 78 1.31 (0.12-2.07) 0.13
Factor V (IU/mL) 0.50-1.50 6 1.15 (0.38-1.61) 35 0.86 (0.31-1.89) 0.41 9 1.39 (0.71-1.84) 78 1.35 (0.81-2.40) 0.67
Factor VII (IU/mL) 0.60-1.40 6 0.74 (0.30-0.80) 33 0.65 (0.33-0.92) 0.45 9 0.97 (0.33-1.53) 78 1.12 (0.54-1.98) 0.16
Factor IX (IU/mL) 0.60-1.50 6 1.23 (0.91-1.87) 33 1.16 (0.61-2.08) 0.47 9 1.62 (1.03-2.01) 78 1.79 (0.41-2.66) 0.41
Factor X (IU/mL) 0.60-1.40 6 0.77 (0.57-0.94) 33 1.05 (0.14-1.62) 0.07 9 1.22 (0.67-1.66) 78 1.56 (0.62-2.52) <0.05
TAT (ug/L) 1.0-4.1 6 9.3 (4.0-56.7) 33 15.1 (3.6-60.0) 0.18 9 6.0 (2.6-22.0) 74 4.5 (1.6-414.0) 0.57
F1+2 (pmol/L) 69-229 6 549 (104-1500) 33 576 (145-1500) 0.78 3 343 (251-1339) 27 190 (70-521) <0.05
F1+2 (nmol/L) 0.44-1.11 6 1.52 (0.99-5.36) 49 1.08 (0.49-20.54) 0.07
PAP (ug/L) 120-700 6 838 (288-1247) 33 634 (317-2318) 0.63 9 306 (3-1403) 74 251 (51-1023) 0.78
ON: osteonecrosis. p values: Mann-Whitney U-test. 
study design, future prospective studies are necessary to
validate the contribution of these age-related coagula-
tion aberrations in the development of ON and the role
of free protein S levels has to be established.
In conclusion, the present study indicates that a
hypercoagulable state may result from a lower dexam-
ethasone-related increase of antithrombin and protein
S and the subsequent decline of these anticoagulants
below normal levels after introduction of asparaginase.
This therapy-induced hypercoagulable state may con-
tribute to the development of symptomatic ON, espe-
cially in teenagers.
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